
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is experiencing a catalyst-rich year with multiple FDA approvals and upcoming PDUFA decisions. The company is focused on radiopharmaceutical products that assist in finding, fighting, and following diseases, making it a promising prospect for clinical settings. With a strong portfolio and expanding global reach, analysts have increased their estimates following a strong first quarter. As Lantheus prepares for a defense-to-offense shift in 2027, investors can expect to see significant revenue and EPS growth, making the stock an attractive opportunity.
Bears say
Lantheus Holdings is heavily dependent on two leading products that face competition from notable players and any disruptions to distribution or supply could significantly hurt the company's financial profile. Furthermore, reimbursement and regulatory risks could further impact the financials of the company. While the company does have a promising pipeline addressing the Alzheimer's diagnostic market, significant contributions are not expected for 2-3 years, and any interim data readouts may only generate investor interest at this time. Overall, Lantheus Holdings faces significant challenges in maintaining and growing its market presence, leading to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares